Comparison of the effect of intralesional injection of triamcinolone acetonide with the simultaneous combination of triamcinolone acetonide and 5-fluoracil

Comparison of the effect of intralesional injection of triamcinolone acetonide with the simultaneous combination of triamcinolone acetonide and 5-fluoracil in the treatment of hypertrophic scars

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N189

Enrollment

Registered

2022-10-25

Start date

2022-11-16

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic scar.

Interventions

Intervention 1: In the first intervention group, 20 mg of triamcinolone acetonide (manufactured by Alborz Company) will be used inside the lesion once every four weeks for 6 treatment sessions (that i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Informed consent

Exclusion criteria

Exclusion criteria: Patients under treatment for the last 6 months Pregnant patients or those planning to become pregnant Lactating women Chronic kidney disease patients or those with any abnormal changes in CBC or liver function tests

Design outcomes

Primary

Measure	Time frame
Intensity of itching of the lesion. Timepoint: First, fourth and sixth week. Method of measurement: Based on examination and questioning of the patient.;Redness intensity of the lesion. Timepoint: First, fourth and sixth week. Method of measurement: Based on examination.;Length, width and height of the lesion. Timepoint: First, fourth and sixth week. Method of measurement: Based on examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdolhamid Ebrahimi

Kermanshah University of Medical Sciences

pamiebi1377@gmail.com+98 83 3427 4618

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026